Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
When do you consider systemic therapy for patients with progressive fibrosing mediastinitis?
Related Questions
What is your approach to managing ILD associated with inflammatory bowel disease?
What are your thoughts on using abatacept for RA-associated ILD in a patient undergoing treatment for CLL with zanubrutinib, and how would you assess the potential increased risk of infection in this context?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
What criteria do you use to decide when to perform a BAL in hypersensitivity pneumonitis?
Is it still significant to denote the etiology of ILD in a patient with PPF?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
